SCHEMBL23286101

SCHEMBL23286101

CC(C)[C@H](NC(=O)CCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(CO)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAP Q12884 5/20 0.42
▸ FURIN P09958 3/20 0.37
▸ NPY5R Q15761 4/20 0.36
▸ NPY4R P50391 4/20 0.36
▸ NPY1R P25929 3/20 0.36
▸ NPY2R P49146 1/20 0.36
▸ MAP1LC3B Q9GZQ8 2/20 0.36
▸ HTT P42858 1/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC10 Q969S8 1/20 0.34
▸ HDAC11 Q96DB2 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ HDAC9 Q9UKV0 1/20 0.34
▸ HDAC5 Q9UQL6 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24848129 0.98 FAP (0.44) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL16266184 0.97 FAP (0.44) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL21416485 0.97 FAP (0.44) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL15246622 0.97 FAP (0.44) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL3244447 0.97 FAP (0.44) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL18244335 0.96 FAP (0.40) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL18244334 0.96 FAP (0.40) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL26423172 0.94 FAP (0.42) FAPFURINNPY5RNPY4RNPY1R
SCHEMBL23477434 0.93 FAP (0.39) FAPFURINMAP1LC3BHTTROCK2
SCHEMBL23943367 0.93 FAP (0.39) FAPFURINNPY5RNPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128167-A1 OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF MABPLEX INTERNATIONAL, LTD. (CN) 2023-04-27 — — US disclosed
EP-3838913-A1 OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR MabPlex International Co., Ltd. (CN) 2021-06-23 — — EP disclosed
WO-2021077317-A1 OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR 烟台迈百瑞国际生物医药股份有限公司 2021-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128167-A1 OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF VIP, DNPEP, PREP FAP 70/4885FURIN 15/4885NPY5R 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback